

Article

Analgesic and Anti-Inflammatory Activities of Salicylaldehyde 2-Chlorobenzoyl Hydrazone (H₂LASSBio-466), Salicylaldehyde 4-Chlorobenzoyl Hydrazone (H₂LASSBio-1064) and Their Zinc(II) Complexes

Walfrido Bispo Júnior ¹, Magna S. Alexandre-Moreira ¹, Marina A. Alves ², Anayive Perez-Rebolledo ³, Gabrieli L. Parrilha ³, Eduardo E. Castellano ⁴, Oscar E. Piro ⁵, Eliezer J. Barreiro ², Lídia Moreira Lima ² and Heloisa Beraldo ^{3,*}

¹ LaFI Laboratório de Farmacologia e Imunidade, Instituto de Ciências Biológicas e da Saúde, Universidade Federal de Alagoas, Maceió, AL, Brazil

² LASSBio Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio, <http://www.farmacia.ufrj.br/lassbio/>), Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, P. O. Box 68024, 21944-971, Rio de Janeiro, RJ, Brazil

³ Departamento de Química, Universidade Federal de Minas Gerais, 31270-901, Belo Horizonte, Brazil

⁴ Instituto de Física de São Carlos, Universidade de São Paulo, 13560-970, São Carlos, SP, Brazil

⁵ Departamento de Física, Facultad de Ciencias Exactas, Universidad Nacional de La Plata and Instituto IFLP (CONICET – CCT La Plata), C.C. 67, 1900 La Plata, Argentina

* Author to whom correspondence should be addressed; E-Mail: hberaldo@ufmg.br; Tel.: 55-31-3409-5740; Fax: 55-31-3409-5700.

Received: 27 June 2011; in revised form: 2 August 2011 / Accepted: 11 August 2011 /

Published: 15 August 2011

Abstract: Salicylaldehyde 2-chlorobenzoyl hydrazone (H₂LASSBio-466), salicylaldehyde 4-chlorobenzoyl hydrazone (H₂LASSBio-1064) and their complexes [Zn(LASSBio-466)H₂O]₂ (**1**) and [Zn(HLASSBio-1064)Cl]₂ (**2**) were evaluated in animal models of peripheral and central nociception, and acute inflammation. All studied compounds significantly inhibited acetic acid-induced writhing response. Upon coordination the anti-nociceptive activity was favored in the complex **1**. H₂LASSBio-466 inhibited only the first phase of the formalin test, while **1** was active in the second phase, like indomethacin, indicating its ability to inhibit nociception associated with the inflammatory response. Hence coordination to zinc(II) altered the pharmacological profile of H₂LASSBio-466.

H₂LASSBio-1064 inhibited both phases but this effect was not improved by coordination. The studied compounds did not increase the latency of response in the hot plate model, indicating their lack of central anti-nociceptive activity. All compounds showed levels of inhibition of zymosan-induced peritonitis comparable or superior to indomethacin, indicating an expressive anti-inflammatory profile.


Keywords: acylhydrazones; zinc(II) complexes; analgesic activity; anti-inflammatory activity

1. Introduction

Inflammation is a response of the immune system to physical and/or chemical and/or biological injury, understanding by injury any process able to cause tissue or cellular damages. The types of inflammation (*i.e.* acute or chronic) differ by cause, mechanism, outcome, and intensity. It is well known that while acute inflammation has a physiological role in normal circumstances, chronic inflammation exerts detrimental effects on the functional status of cells and tissues. As a consequence inflammatory processes take part in a huge number of diseases such as atherosclerosis, Alzheimer disease, Parkinson disease, cancer, asthma, arthritis and so on [1-3].

Zinc is one of the most prevalent trace elements in the human body. It has been shown to be essential to the structure and function of a large number of macromolecules and for a variety of enzymatic reactions, which mediate a wide range of physiological processes [4,5]. These include production of collagen and other extracellular matrix proteins, modulation of immunoregulatory (e.g., T and B lymphocytes, macrophages, and antigen-presenting dendritic cells) and inflammatory (e.g., eosinophils, neutrophils, and mast cells) cells function. As a consequence, zinc may be considered an important immunoregulatory agent with anti-apoptotic and anti-inflammatory activities [6].

Figure 1. Generic structure of salicylaldehyde 2-chlorobenzoyl hydrazone (H₂LASSBio-466) and its regioisomer salicylaldehyde 4-chlorobenzoyl hydrazone (H₂LASSBio-1064).



In the context of a research program that aims to contribute to the discovery of new anti-inflammatory and analgesic drug candidates, we describe the synthesis of zinc(II) complexes with salicylaldehyde 2-chlorobenzoyl hydrazone (H₂LASSBio-466) and its regioisomer salicylaldehyde 4-

chlorobenzoyl hydrazone ($\text{H}_2\text{LASSBio-1064}$) (Figure 1), together with a pharmacological evaluation of all acylhydrazones and zinc(II) complexes in animal models of peripheral and central nociception and acute inflammation.

2. Results and Discussion


2.1. Formation of the Zinc(II) Complexes 1 and 2

Microanalyses and molar conductivity data are compatible with the formation of $[\text{Zn}(\text{LASSBio-466})\text{H}_2\text{O}]$ and $[\text{Zn}(\text{HLASSBio-1064})\text{Cl}]$. In the first compound a di-anionic acylhydrazone is attached to the metal center upon deprotonation at N(2)-H and O(1)-H. The remaining coordination site is occupied by a water molecule, as indicated by the infrared spectrum of the compound (Section 2.3). In the second, a mono-anionic acylhydrazone is attached to the metal upon deprotonation at O(1)-H, together with a chloride ion.

Upon recrystallization of $[\text{Zn}(\text{HLASSBio-1064})\text{Cl}]$ in 1:9 DMSO-acetone, crystals of $[\text{Zn}_2(\text{LASSBio-1064})_2(\text{H}_2\text{O})_2] \cdot [\text{Zn}_2(\text{LASSBio-1064})_2(\text{DMSO})_4]$ were obtained. The compound consists of two center symmetric binuclear zinc(II) complexes hosted in the same lattice, as previously reported by some of us [7]. We had also obtained $[\text{Zn}(\text{LASSBio-1064})]_2$, which is a phenoxo-bridged dimer since the monomer would contain zinc(II) with coordination number three, which is very unlikely [7]. Hence $[\text{Zn}(\text{HLASSBio-1064})\text{Cl}]$ most probably also exists as a dimer, $[\text{Zn}(\text{HLASSBio-1064})\text{Cl}]_2$.

We now obtained $[\text{Zn}(\text{LASSBio-466})(\text{H}_2\text{O})]$, in which a water molecule occupies the fourth coordination position, like in the first center symmetric unit of $[\text{Zn}_2(\text{LASSBio-1064})_2(\text{H}_2\text{O})_2] \cdot [\text{Zn}_2(\text{LASSBio-1064})_2(\text{DMSO})_4]$. Therefore, $[\text{Zn}(\text{LASSBio-466})(\text{H}_2\text{O})]$ is also probably a phenoxo-bridged dimer, $[\text{Zn}(\text{LASSBio-466})(\text{H}_2\text{O})]_2$. Considering that dimerization is favored in this class of compounds [7], the zinc(II) complexes are hereafter formulated as $[\text{Zn}(\text{LASSBio-466})(\text{H}_2\text{O})]_2$ (**1**) and $[\text{Zn}(\text{HLASSBio-1064})\text{Cl}]_2$ (**2**).

Figure 2. Molecular plot of LASSBio-466 showing the labeling scheme of the non-H atoms and their displacement ellipsoids at the 50% probability level.



2.2. Crystal Structure of $H_2LASSBio-466$

Crystal data and refinement results are summarized in Table 1. Figure 2 is an ORTEP [8] drawing of the molecule and Table 2 shows the corresponding intra-molecular bond distances and angles.

Table 1. Crystal data and structure solution methods and refinement results for salicylaldehyde 2-chlorobenzoyl hydrazone ($H_2LASSBio-466$).

Compound		$H_2LASSBio-466$
Empirical Formula		$C_{14}H_{11}ClN_2O_2$
Formula Weight		274.70
Temperature, K		294(2)
Crystal System		Monoclinic
Space Group		$P2_1/c$
Unit cell dimensions	a, Å	9.889(1)
	b, Å	13.360(2)
	c, Å	10.079(1)
	α , °	90
	β , °	93.10(1)
	γ , °	90
Volume, Å ³		1329.7(3)
Z, Density calc., Mg/m ³		4, 1.372
Absorption coefficient, mm ⁻¹		0.286
F(000)		568
Crystal size, mm		0.20 × 0.12 × 0.08
Crystal color / shape		Colorless / prism
θ range for data coll.		3.05 to 24.08°
Index range		$-10 \leq h \leq 11$
		$-15 \leq k \leq 15$
		$-11 \leq l \leq 11$
Completeness, $\theta = 26.37^\circ$		99.6 %
Max. / min. transmission		0.977 / 0.945
Goodness-of-fit on F^2		1.016
Reflec. collect./unique (R_{int})		5646/2095 (0.032)
Observed reflections [$I > 2\sigma(I)$]		1612
Weights, w		$[\sigma^2(F_o^2) + (0.088P)^2 + 0.22P]^{-1}$ $P = [\text{Max}((F_o^2, 0) + 2F_c^2)]/3$
Data / restraints / parameters		2095 / 0 / 184
Final R indexes ^a [$I > 2\sigma(I)$]		$R_I = 0.0474$, $wR_2 = 0.1296$
R indices (all data)		$R_I = 0.0637$, $wR_2 = 0.1479$
Extinction coefficient		0.07(1)
Larg. peak & hole, e Å ⁻³		0.180 / -0.246

^a R indices defined as: $R_I = \sum ||F_o| - |F_c|| / \sum |F_o|$, $wR_2 = [\sum w(F_o^2 - F_c^2)^2 / \sum w(F_o^2)^2]^{1/2}$.

The phenyl rings show a delocalized bonding structure, with C-C distances ranging from 1.370(3) to 1.388(3) Å for the chlorine-containing phenyl, where $d(C_{ph}-Cl) = 1.724(3)$ Å, and from 1.359(4) to 1.400(3) Å for the phenol ring, where $d(C_{ph}-OH) = 1.353(3)$ Å. We found for the carbonyl C(8)=O(2) and C(7)=N(1) groups distances of 1.226(2) and 1.272(3) Å, respectively, as expected for formal double bonds. The N(1)-N(2) length of 1.376(3) Å agrees with the single bond character of this link. The molecule conformation is stabilized by a strong intra-molecular O-H...N bond [$d(O(1)\cdots N(1)) =$

2.632 Å, $\angle(\text{O}(1)\text{-H}(1)\cdots\text{N}(1)) = 145.7^\circ$. As shown in Figure 2 the hydrazone adopts the *E* configuration in the crystal state.

Table 2. Bond lengths [Å] and angles [°] for salicylaldehyde 2-chlorobenzoyl hydrazone (H₂LASSBio-466).

Atoms	Bond lengths (Å)	Atoms	Angles (°)
Cl-C(10)	1.724(3)	O(2)-C(8)-C(9)	123.2(2)
O(1)-C(1)	1.353(3)	N(1)-C(7)-C(2)	121.1(2)
O(2)-C(8)	1.226(3)	N(2)-C(8)-C(9)	114.7(2)
N(1)-N(2)	1.376(3)	N(1)-N(2)-C(8)	118.6(2)
N(1)-C(7)	1.272(3)	N(2)-N(1)-C(7)	117.2(2)
N(2)-C(8)	1.346(3)	C(1)-C(2)-C(3)	118.3(2)
C(1)-C(2)	1.400(3)	C(1)-C(2)-C(7)	122.2(2)
C(1)-C(6)	1.384(4)	C(1)-C(6)-C(5)	120.5(3)
C(2)-C(3)	1.390(3)	C(2)-C(1)-C(6)	119.7(2)
C(2)-C(7)	1.445(3)	C(2)-C(3)-C(4)	121.1(3)
C(3)-C(4)	1.374(4)	C(3)-C(4)-C(5)	119.5(3)
C(4)-C(5)	1.371(5)	C(3)-C(2)-C(7)	119.5(2)
C(5)-C(6)	1.359(4)	C(4)-C(5)-C(6)	120.8(3)
C(8)-C(9)	1.494(3)	C(8)-C(9)-C(10)	122.4(2)
C(9)-C(10)	1.393(3)	C(8)-C(9)-C(14)	119.9(2)
C(9)-C(14)	1.388(3)	C(9)-C(10)-Cl	120.8(2)
C(10)-C(11)	1.381(4)	C(9)-C(10)-C(11)	121.1(3)
C(11)-C(12)	1.376(4)	C(9)-C(14)-C(13)	121.5(3)
C(12)-C(13)	1.371(4)	C(10)-C(9)-C(14)	117.6(2)
C(13)-C(14)	1.370(3)	C(10)-C(11)-C(12)	119.5(3)
		C(11)-C(10)-Cl	118.1(2)
		C(11)-C(12)-C(13)	120.3(3)
		C(12)-C(13)-C(14)	119.9(3)
		O(1)-C(1)-C(2)	122.4(2)
		O(1)-C(1)-C(6)	118.0(2)
		O(2)-C(8)-N(2)	122.1(2)

The solid is further stabilized by a medium-strength inter-molecular N-H $\cdots$ O_{carbonyl} bond [$d(\text{N}(2)\cdots\text{O}(2)) = 2.885$ Å, $\angle(\text{N}(2)\text{-H}(2)\cdots\text{O}(2')) = 166.2^\circ$] between neighboring molecules, symmetry-related to each other through a glide plane, involving the imine group of a molecule as a donor and the carbonyl oxygen of the other as an acceptor. This gives rise to a polymeric structure that extends along the crystal *c*-axis (see Figure 2).

2.3. Spectroscopic Characterization

The vibrations at 3450–3436 cm^{−1} in the infrared spectra of the free acylhydrazones attributed to $\nu(\text{O-H})$ disappear in those of the complexes, in accordance with deprotonation of the phenol group [9]. The $\nu(\text{C=O})$ absorption at 1657 cm^{−1} in the spectrum of the H₂LASSBio-466 was not found in the spectrum of the complex **1**, indicating coordination of an enolate oxygen [10,11]. The $\nu(\text{C=O})$ absorption at 1676 cm^{−1} in the spectrum of the H₂LASSBio-1064 shifts to 1618 cm^{−1} in the spectrum of **2**, indicating coordination through the carbonyl oxygen [10–13]. The vibrations attributed to $\nu(\text{C=N})$ at 1625 and 1624 cm^{−1} in the infrared spectra of the hydrazones shift to 1614 and 1611 cm^{−1}, respectively, in the spectra of the complexes, in agreement with coordination of the azomethine

nitrogen [10–13]. A new absorption at 1604 cm^{-1} in the spectrum of complex **1** was attributed to the $\nu(\text{OH}_2)$ vibration.

The NMR spectra of the acylhydrazones and their zinc(II) complexes were recorded in $\text{DMSO-}d_6$. The ^1H resonances were assigned on the basis of chemical shifts and multiplicities. The carbon type (C, CH) was determined by using distortionless enhancement by polarization transfer (DEPT 135) experiments. The assignments of the protonated carbons were made by 2D heteronuclear multiple quantum coherence experiments (HMQC).

The signals of all hydrogens and carbons are duplicated in the ^1H - and ^{13}C -NMR spectra of $\text{H}_2\text{LASSBio-466}$, indicating the presence of the *E* and *Z* configurational isomers in the $\text{DMSO-}d_6$ solution. In fact, two N(2)-H signals were observed at δ 11.05 and 9.84 ppm, which were attributed to the *Z* and *E* isomers, respectively. In the first N(2)-H is hydrogen bonded to the phenol oxygen, while in the latter it is hydrogen bonded to the solvent [10–13]. Only one signal was found for each hydrogen and each carbon in the ^1H - and ^{13}C -NMR spectra of $\text{H}_2\text{LASSBio-1064}$. These signals are compatible with the presence of the *E* configurational isomer.

Only one signal was observed for each hydrogen and each carbon in the spectra of complexes **1–2**. The O(1)-H signals were absent in the spectra of all complexes, in agreement with deprotonation and formation of a phenolate group. In the spectrum of **1** the N(2)-H signal disappears, suggesting deprotonation of the hydrazone upon coordination. Hence in **1** a di-anionic hydrazone ligand is attached to the zinc(II) center. In the spectrum of **2** the N(2)-H signal was observed, according with the presence of a mono-anionic hydrazone ligand. In the ^1H -NMR spectra of the complexes the signals of all hydrogens undergo significant shifts in relation to their positions in the free hydrazones. Similarly, the signals of C=N, C=O and the phenol carbons undergo significant shifts in complexes **1** and **2**, indicating coordination through the $\text{O}_{\text{phenol}}\text{-N-O}$ chelating system. Hence in **1–2** the hydrazones adopt the *E* configuration.

2.4. Anti-Nociceptive Activity of $\text{H}_2\text{LASSBio-466}$, $\text{H}_2\text{LASSBio-1064}$, $[\text{Zn}(\text{LASSBio-466})\text{H}_2\text{O}]_2$ (**1**) and $[\text{Zn}(\text{HLASSBio-1064})\text{Cl}]_2$ (**2**)

The anti-nociceptive profiles of the free ligands $\text{H}_2\text{LASSBio-466}$, $\text{H}_2\text{LASSBio-1064}$ and their zinc(II) complexes **1** and **2** were evaluated using three well-accepted pain models, namely acetic acid-induced writhing, formalin-induced nociception and hot plate test. The acetic acid-induced abdominal writhing and hot-plate test have been reported to be useful to investigate peripheral and central activity, respectively, while the formalin-induced nociception is valuable to detect both effects, including inflammatory pain.

All compounds were evaluated at a dose of $100\text{ }\mu\text{mol/kg}$ (p.o). Indomethacin, a COX-1 selective inhibitor ($100\text{ }\mu\text{mol}\cdot\text{kg}^{-1}$, p.o.) and dipyrone, a COX-3 selective inhibitor ($100\text{ }\mu\text{mol}\cdot\text{kg}^{-1}$, p.o.) were used as standard drugs in the peripheral nociception models, while morphine ($15\text{ }\mu\text{mol}\cdot\text{kg}^{-1}$, i.p.) was used as standard in the hot-plate test. The analgesic activity of $\text{H}_2\text{LASSBio-466}$, its regioisomer $\text{H}_2\text{LASSBio-1064}$, and their complexes $[\text{Zn}(\text{LASSBio-466})\text{H}_2\text{O}]_2$ (**1**) and $[\text{Zn}(\text{HLASSBio-1064})\text{Cl}]_2$ (**2**) was initially evaluated employing the acetic acid-induced abdominal writhing model in mice and compared with those of the standards [14].

As shown in Table 3, all compounds produced marked inhibition of acetic acid-induced writhing response. However, the anti-nociceptive activity appears to have been favored by complex formation in the case of complex **1**, given its increased activity compared to the H₂LASSBio-466 free ligand.

Table 3. Effect of H₂LASSBio-466, its regioisomer H₂LASSBio-1064, their zinc(II) complexes, indomethacin and dipyron (100 $\mu\text{mol}\cdot\text{kg}^{-1}$, p.o.) on the 0.6% acetic acid-induced abdominal constrictions in mice, for a period of 25 min.

Substance	n	Writhing number Mean $\pm$ S.E.M.	% of inhibition Mean $\pm$ S.E.M.
Control	6	37.5 $\pm$ 1.4	—
Indomethacin	6	6.0 $\pm$ 3.1 **	84.0 $\pm$ 8.3 **
Dipyron	6	8.3 $\pm$ 2.7 **	77.8 $\pm$ 7.2 **
H ₂ LASSBio-466	6	14.8 $\pm$ 2.2 **	60.4 $\pm$ 6.0 **
H ₂ LASSBio-1064	6	7.0 $\pm$ 1.1 **	81.3 $\pm$ 3.0 **
[Zn(LASSBio-466)H ₂ O] ₂ (1)	6	6.6 $\pm$ 1.4 **	82.3 $\pm$ 3.7 **
[Zn(HLASSBio-1064)Cl] ₂ (2)	6	10.8 $\pm$ 2.3 **	70.9 $\pm$ 6.2 **

Data are expressed as mean $\pm$ S.E.M. Statistical differences between the treated and the control groups were evaluated by ANOVA and Dunnett tests and the asterisks denote the levels of significance in comparison with control groups, ** P < 0.01.

The neurogenic and inflammatory pain was evaluated using the formalin test and analyzing the first and the second phases of the nociceptive response, respectively [15]. In this model, H₂LASSBio-466 was effective in inhibiting only the first phase, while [Zn(LASSBio-466)H₂O]₂ (**1**), like indomethacin, was active in the second phase, indicating its ability to inhibit nociception associated with inflammatory response (Table 4). H₂LASSBio-1064 was able to inhibit both neurogenic and inflammatory phases anticipating a distinct pharmacological profile. However this effect decreases on coordination to zinc(II) in complex **2**. These results suggest that coordination seems to be a good strategy to improve the antinociception profile of the prototype H₂LASSBio-466 associated with an inflammatory pain.

Table 4. Effect of prototypes H₂LASSBio-466, H₂LASSBio-1064, their zinc(II) complexes and indomethacin (100 $\mu\text{mol}\cdot\text{kg}^{-1}$, p.o.) on formalin (2.5%) test in mice.

Substance	n	Phase 1 Mean $\pm$ S.E.M.	Phase 2 Mean $\pm$ S.E.M.	% of inhibition (Mean $\pm$ S.E.M.)	
				Phase 1	Phase 2
Control	5	54.8 $\pm$ 2.3	227.6 $\pm$ 22.7	—	—
Indomethacin	5	57.1 $\pm$ 8.5	115.9 $\pm$ 3.3 *	0	49.1 $\pm$ 1.4 *
H ₂ LASSBio-466	5	29.3 $\pm$ 8.3 **	182.4 $\pm$ 17.4	46.5 $\pm$ 8.3 **	19.8 $\pm$ 9.7
H ₂ LASSBio-1064	5	25.7 $\pm$ 4.9 *	117.0 $\pm$ 19.1 *	53.1 $\pm$ 8.9 *	48.5 $\pm$ 8.4 *
[Zn(LASSBio-466)H ₂ O] ₂ (1)	5	40.6 $\pm$ 12.7	142.8 $\pm$ 23.1 *	25.9 $\pm$ 15.7	37.3 $\pm$ 10.1 *
[Zn(HLASSBio-1064)Cl] ₂ (2)	5	39.6 $\pm$ 7.8	161.3 $\pm$ 36.0	27.7 $\pm$ 13.1	29.2 $\pm$ 13.9

Data are expressed as mean $\pm$ S.E.M. Statistical differences between the treated and the control groups were evaluated by test t and Mann-Whitney tests and the asterisks denote the levels of significance in comparison with control groups, * P < 0.05 and ** P < 0.01.

In order to investigate an occasional central anti-nociceptive activity for prototypes H₂LASSBio-466, H₂LASSBio-1064 and their zinc(II) complexes, the studied compounds were evaluated in the hot

plate test using morphine ($15 \mu\text{mol}\cdot\text{kg}^{-1}$, i.p.) as standard [16]. As shown in Table 5, these compounds did not increase the latency of response significantly, showing that they do not present activity in the supra-spinal analgesia, while morphine induced a marked increase in the latency of the animals at 60 min (9.0 ± 1.6 s), 90 min (7.4 ± 0.8 s), 120 min (5.3 ± 0.8 s) and 150 min (2.5 ± 0.2 s). These results indicate that the studied compounds do not have any central anti-nociceptive activity.

Table 5. Time course effect of prototypes H₂LASSBio-466, H₂LASSBio-1064, their zinc(II) complexes ($100 \mu\text{mol}\cdot\text{kg}^{-1}$, p.o.) and morphine ($15 \mu\text{mol}\cdot\text{kg}^{-1}$, i.p.) on hot-plate test in mice.

Substance	n	Mean $\pm$ S.E.M.				
		0 min	60 min	90 min	120 min	150 min
Control	6	2.8 ± 0.2	2.9 ± 0.3	1.6 ± 0.2	2.3 ± 0.40	1.7 ± 0.1
Morphine	6	1.8 ± 0.5	9.0 ± 1.6 *	7.4 ± 0.8 *	5.3 ± 0.8 *	2.5 ± 0.2
H ₂ LASSBio-466	6	2.1 ± 0.21	2.3 ± 0.4	2.1 ± 0.2	2.2 ± 0.2	2.6 ± 0.1
H ₂ LASSBio-1064	6	1.7 ± 0.18	2.6 ± 0.2	2.1 ± 0.2	2.5 ± 0.3	3.5 ± 0.3
[Zn(LASSBio-466)H ₂ O] ₂ (1)	6	2.1 ± 0.2	4.2 ± 0.8	2.4 ± 0.6	3.6 ± 0.6	5.4 ± 1.2
[Zn(HLASSBio-1064)Cl] ₂ (2)	6	1.5 ± 0.1	2.0 ± 0.5	2.3 ± 0.5	2.9 ± 1.0	1.9 ± 0.2

Data are expressed as mean $\pm$ S.E.M. Statistical differences between the treated and the control groups were evaluated by ANOVA and Dunnett tests and the asterisks denote the levels of significance in comparison with control groups, * $P < 0.05$.

To better assess the potential anti-inflammatory activity of the free acylhydrazones and their zinc(II) complexes, the zymosan-induced peritonitis assay was performed [17]. As seen in Table 6, all compounds showed some level of inhibition in this cell migration model comparable or superior to indomethacin.

Table 6. Effect of prototypes H₂LASSBio-466, H₂LASSBio-1064, their zinc(II) complexes and indomethacin ($100 \mu\text{mol}\cdot\text{kg}^{-1}$, p.o.) on the zymosan-induced peritonitis in mice.

Substance	n	Cell Number $\times 10^6/\text{mL}$	% of inhibition
		Mean $\pm$ S.E.M.	Mean $\pm$ S.E.M.
Control	7	38.0 ± 1.0	—
Saline	7	5.0 ± 0.8	—
Indomethacin	7	17.7 ± 1.0 **	53.4 ± 2.7 **
H ₂ LASSBio-466	7	11.4 ± 1.4 **	70.0 ± 3.8 **
H ₂ LASSBio-1064	7	8.4 ± 0.9 **	77.8 ± 2.4 **
[Zn(LASSBio-466)H ₂ O] ₂ (1)	7	10.7 ± 1.8 **	71.8 ± 4.9 **
[Zn(HLASSBio-1064)Cl] ₂ (2)	7	13.4 ± 1.5 **	64.7 ± 4.0 **

Data are expressed as mean $\pm$ S.E.M. Statistical differences between the treated and the control groups were evaluated by ANOVA and Dunnett tests and the asterisks denote the levels of significance in comparison with control groups, ** $P < 0.01$.

In fact, H₂LASSBio-466, H₂LASSBio-1064, [Zn(LASSBio-466)H₂O]₂ and [Zn(HLASSBio-1064)Cl]₂, presented 70.0%, 77.8%, 71.8% and 64.7% of inhibition, respectively, while indomethacin inhibited cell-migration by 53.4%.

3. Experimental

3.1. General

All common chemicals were purchased from Aldrich and used without further purification. Partial elemental analyses were performed on a Perkin Elmer CHN 2400 analyzer. A YSI model 31 conductivity bridge was employed for molar conductivity measurements (1×10^{-3} mol L⁻¹, DMF). Infrared spectra (4000–400 cm⁻¹) were recorded on a Perkin Elmer FT-IR Spectrum GX spectrometer using KBr plates. NMR spectra were obtained with a Bruker DPX-200 Avance (200 MHz) spectrometer using DMSO-*d*₆ as the solvent and TMS as internal reference.

3.2. Synthesis of H₂LASSBio-466 and H₂LASSBio-1064

The synthesis of H₂LASSBio-466 and H₂LASSBio-1064 were performed using a previously described methodology [18]. Briefly, salicylaldehyde (2-hydroxybenzaldehyde) was added to a solution of 2-chlorobenzohydrazide or 4-chlorobenzohydrazide (an equimolar amount) in absolute ethanol containing one drop of 37% hydrochloric acid. The mixture was stirred at room temperature for 2 hours until extensive precipitation was observed. Next, the solvent was partially concentrated at reduced pressure and the resulting mixture was poured into cold water. The precipitate formed was filtered out and dried under vacuum producing the desired (*E,Z*)-salicylaldehyde 2-chlorobenzoyl hydrazone (H₂LASSBio-466) and (*E*)-salicylaldehyde 4-chlorobenzoyl hydrazone (H₂LASSBio-1064) in 87% and 91% yield, respectively. The melting point and ¹H-NMR data for both compounds were in agreement with previous reports [19,20].

3.3. Synthesis of Zinc(II) Complexes

3.3.1. Synthesis of [Zn(LASSBio-466)H₂O]₂ (1) and [Zn(HLASSBio-1064)Cl]₂ (2)

Complexes **1** and **2** were obtained by mixing an ethanol solution of the desired hydrazone with zinc chloride and triethylamine in 1:1:1 ligand-to-metal-to-triethylamine molar ratio. The resulting solids were washed with ethanol followed by diethylether and then dried *in vacuo*.

[Zn(LASSBio-466)H₂O]₂ (**1**). Yield 68%. Yellow solid. Anal. Calc. for C₂₈H₂₂N₄O₆Cl₂Zn₂ (712.18): C, 47.26%; H, 2.85%; N, 7.40%. Found: C, 47.22%; H, 3.11%; N, 7.87%. M.P. > 300 °C. Molar conductivity: 8.23 Ω⁻¹cm² mol⁻¹. IR: ν(C=N) 1614, ν(Zn-OH₂) 1604, ν(phenolic, CO) 1329. ¹H-NMR: δ (ppm) = 7.54 (1H, H7), 7.47–7.59 (1H, H14), 7.52 (1H, H11), 7.51 (1H, H5), 7.44–7.47 (1H, H3), 7.32 (1H, H13), 7.28 (1H, H13), 6.79 (1H, H6), 6.70 (1H, H4). ¹³C-NMR: δ (ppm) = 169.73 (C8), 158.02 (C1), 150.59 (C7), 135.87 (C10), 135.09 (C12), 134.37 (C13), 131.38 (C5), 130.35 (C11), 129.81 (C14), 127.48 (C3), 119.69 (C9, C2), 119.35 (C4), 118.37 (C6).

[Zn(HLASSBio-1064)Cl]₂ (**2**). Yield 71%. Yellow solid. Anal. Calc. for C₂₈H₂₀N₄O₄Cl₄Zn₂ (749.11): C, 44.72%; H, 2.24%; N, 7.10%. Found: C, 44.89%; H, 2.69%; N, 7.48%. M.P. > 300 °C. Molar conductivity: 11.35 Ω⁻¹cm² mol⁻¹. IR: ν(N-H) 3179, ν(C=O) 1618, ν(C=N) 1611, ν(phenolic, CO) 1281. ¹H-NMR: δ (ppm) = 8.99 (1H, H7), 8.01 (2H, H11, H13), 7.59 (2H, H10, H14), 7.38 (1H, H3),

7.24 (1H, H5), 6.73 (1H, H6), 6.89 (1H, H4). ^{13}C -NMR: δ (ppm) = 168.88 (C8), 166.81 (C1), 155.61 (C7), 136.83 (C12), 131.62 (C5), 129.68 (C10,C14), 129.58 (C3), 128.79 (C11, C13), 119.53 (C4), 118.75 (C9, C2), 116.54 (C6).

3.4. X-ray Crystallography

The X-ray diffraction measurements were performed on an Enraf-Nonius Kappa-CCD diffractometer with graphite-monochromated $\text{MoK}\alpha$ ($\lambda = 0.71073 \text{ \AA}$) radiation. Diffraction data were collected (φ and ω scans with κ -offsets) with COLLECT [21]. Integration and scaling of the reflections were performed with HKL DENZO-SCALEPACK [22] suite of programs. The unit cell parameters were obtained by least-squares refinement based on the angular settings for all collected reflections using HKL SCALEPACK. The structure was solved by direct methods with SHELXS-97 [23] and the molecular model refined by full-matrix least-squares procedure on F^2 with SHELXL-97 [24]. The hydrogen atoms were included in the molecular model at stereo-chemical positions and refined with the riding model.

3.5. Anti-nociceptive and anti-inflammatory activities of $\text{H}_2\text{LASSBio-466}$, $\text{H}_2\text{LASSBio-1064}$, $[\text{Zn}(\text{LassBio-466})\text{H}_2\text{O}]_2$ (1) and $[\text{Zn}(\text{HLassBio-1064})\text{Cl}]_2$ (2)

3.5.1. Animals

Experiments were conducted using Swiss mice obtained from the BIOCEN - UFAL breeding unit, weighing 20–30 g each, males or females, adult, with 6 to 8 weeks of age, distributed in groups of up to 6–8 animals for treatment. The animals were maintained with free access to food and water and kept at 25–28 °C under a controlled 12 h light-dark^{−1} cycle. All animals were manipulated according to the norms established by the Ethics Commission - UFAL for handling animals (protocol number: 026681/2009-23).

3.5.2. Writhing Test

This test was performed as described by Collier and coworkers [14]. Acetic acid (0.6%, v/v) was administered i.p. in a volume of $0.1 \text{ mL} \cdot 10 \text{ g}^{-1}$. The number of writhes, a response consisting of contraction of an abdominal wall, pelvic rotation followed by hind limb extension, was counted during continuous observation for 20 min. beginning 5 min. after the acetic acid injection. The prototypes $\text{H}_2\text{LASSBio-466}$, $\text{H}_2\text{LASSBio-1064}$ and their zinc(II) complexes, indomethacin and dipyrone were administered at the dose of $100 \mu\text{mol} \cdot \text{kg}^{-1}$ (p.o), 40 min. before the acetic acid injection. Control group received $10 \text{ mL} \cdot \text{kg}^{-1}$ of vehicle (arabic gum, p.o.). Anti-nociceptive activity was expressed as inhibition percentage of the usual number of writhing observed in control animals.

3.5.3. Formalin-Induced Pain in Mice

The formalin test was performed as described by Hunskaar and Hole [15]. Animals received 20 μL of a 2.5% formalin solution (0.92% formaldehyde in saline) in the ventral surface of the right hind paw. They were observed from 0 to 5 min. (neurogenic phase) and from 15 to 30 min. (inflammatory phase) after injection and the time they spent licking the injected paw was recorded and considered as

indicative of nociception. The prototypes H₂LASSBio-466, H₂LASSBio-1064, their zinc(II) complexes and indomethacin were administered at the dose of 100 $\mu\text{mol}\cdot\text{kg}^{-1}$ (p.o), 40 min. before formalin injection. Control group received 10 $\text{mL}\cdot\text{kg}^{-1}$ of vehicle (arabic gum, p.o.).

3.5.4. Hot-Plate Test

Mice were treated according to the method described by Eddy and Leimbach [16]. Each mouse was placed on the hot plate set at 54 ± 1.0 °C and the time of paw licking was recorded before and 30 min. after oral administration of the tested compounds. The prototypes H₂LASSBio-466, H₂LASSBio-1064 and their zinc(II) complexes were administered at the dose of 100 $\mu\text{mol}\cdot\text{kg}^{-1}$ (p.o). Control group received 10 $\text{mL}\cdot\text{kg}^{-1}$ of vehicle (arabic gum, p.o.). Morphine was also used as a drug standard at the dose of 15 $\mu\text{mol}\cdot\text{kg}^{-1}$ (i.p.). Analgesia was defined as an increase in the latency of paw licking, and the latency times were compared with the values obtained for control. Sixty seconds were taken as the cut-off time to avoid mouse tissue damage.

3.5.5. Zymosan-Induced Peritonitis

Peritoneal inflammation was induced according to the method described by Doherty [17]. A solution of zymosan A (Sigma-Aldrich, 2 $\text{mg}\cdot\text{mL}^{-1}$) was prepared in saline (0.9% NaCl) and injected into the peritoneal cavity of mice (0.5 mL). Six hours after injection of zymosan A, the animals were sacrificed by cervical dislocation and the peritoneal cavity was washed with cold Hank's solution (3 mL). The prototypes H₂LASSBio-466, H₂LASSBio-1064, their zinc(II) complexes and indomethacin were administered at the dose of 100 $\mu\text{mol}\cdot\text{kg}^{-1}$ (p.o), 40 min. before zymosan A injection. The control group received 10 $\text{mL}\cdot\text{kg}^{-1}$ of vehicle (arabic gum, p.o.). The number of cells was quantified using an optical microscope, and a 100 x lens.

3.5.6. Statistical Analysis

Data obtained from animal experiments are represented by mean $\pm$ standard error of the mean (Mean $\pm$ S.E.M.). Statistical differences between the treated and the control groups were evaluated by test t of Student or ANOVA in the tutorial Prisma®. Values were considered significant if * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$.

4. Conclusions

The studied compounds, evaluated at a dose of 100 $\mu\text{mol}/\text{kg}$ (p.o), showed marked inhibition of acetic acid-induced writhing response, with the anti-nociceptive activity being favored by zinc(II) complex formation in the case of complex **1**. The compounds also have antinociception profile associated with inflammatory pain, with no activity in murine analgesic model of central pain. In the formalin model, H₂LASSBio-466 was effective in inhibiting only the first phase, while its zinc(II) complex **1**, like indomethacin, was active in the second phase, indicating its ability to inhibit nociception associated with inflammatory response. Hence coordination to zinc(II) altered the pharmacological profile of H₂LASSBio-466. Moreover, the salicylaldehyde *N*-acylhydrazone

derivatives and their zinc(II) complexes showed comparable or superior inhibition of cell-migration process to indomethacin, indicating an expressive anti-inflammatory profile.

The different activities of the complexes could be explained by their releasing hydrazone at different rates during the assays. In addition, complex **1** contains a di-anionic hydrazone while **2** contains a mono-anionic hydrazone. Hence different electronic effects could also influence the distinct pharmacological profiles of complexes **1** and **2**. In addition, **1** contains a water molecule in the metal coordination sphere while **2** contains a chloride ion. Finally, coordination could in principle alter the bioavailability of the two hydrazones in different manners. The above-mentioned results suggest that further studies on the anti-inflammatory properties of this class of compounds and their zinc(II) complexes should be carried out in order to investigate their mechanism of action

Acknowledgements

The authors are grateful to CNPq, INCT-INOVAR (CNPq proc.573.364/2008-6), FAPESP (Brazil) and to CONICET (Argentina) for financial support. O. E. P. is a Research Fellow of CONICET, Argentina.

Supplementary Material

CCDC 805145 contains the supplementary crystallographic data for salicylaldehyde 2-chlorobenzoyl hydrazone (H₂Lassbio-466). This data can be obtained free of charge via <http://www.ccdc.cam.ac.uk/conts/retrieving.html>, or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; or e-mail: deposit@ccdc.cam.ac.uk.

References

1. Yong, V.W. Inflammation in neurological disorders: A help or a hindrance? *Neuroscientist* **2010**, *16*, 408-420.
2. Kominsky, D.J.; Campbell, E.L.; Colgan, S.P. Metabolic shifts in immunity and inflammation. *J. Immunol.* **2010**, *184*, 4062-4068.
3. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. *Cell* **2010**, *140*, 883-899.
4. Tapiero, H.; Tew, K.D. Trace elements in human physiology and pathology: Zinc and metallothioneins. *Biomed. Pharmacother.* **2003**, *57*, 399-411.
5. Szezyzyk, B.; Kubera, M.; Nowak, G. The role of zinc in neurodegenerative inflammatory pathways in depression. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **2011**, *35*, 693-701.
6. Zalewski, P.D.; Truong-Tran, A.Q.; Grosser, D.; Jayaram, L.; Murgia, C.; Ruffin, R.E. Zinc metabolism in airway epithelium and airway inflammation: basic mechanism and clinical targets. A review. *Pharmacol. Ther.* **2005**, *105*, 127-149.
7. Parrilha, G.L.; Vieira, R.P.; Rebolledo, A.P.; Mendes, I.C.; Lima, L.M.; Barreiro, E.J.; Piro, O.E.; Castellano, E.E.; Beraldo, H. Binuclear zinc(II) complexes with the anti-inflammatory

- compounds salicylaldehyde semicarbazone and salicylaldehyde-4-chlorobenzoyl hydrazone. *Polyhedron* **2011**, *30*, 1891-1898 and references therein.
8. Johnson, C.K. *ORTEP; Report ORNL-3794*; Oak Ridge National Laboratory: Tennessee, 1965.
 9. Salavati-Niasari, M.; Amiri, A. Synthesis and characterization of alumina-supported Mn(II), Co(II), Ni(II) and Cu(II) complexes of bis(salicylaldiminato)hydrazone as catalysts for oxidation of cyclohexene with tert-buthylhydroperoxide. *Appl. Catal. A Gen.* **2005**, *290*, 46-53.
 10. Despaigne, A.A.R.; Da Silva, J.G.; Do Carmo, A.C.M.; Sives, F.; Piro, O.E.; Castellano, E.E.; Beraldo, H. Copper(II) and zinc(II) complexes with 2-formylpyridine-derived hydrazones. *Polyhedron* **2009**, *28*, 3797-3803.
 11. Despaigne, A.A.R.; Vieira, L.F.; Mendes, I.C.; Da Costa, F.B.; Speziali, N.L.; Beraldo, H. Organotin(IV) complexes with 2-acetylpyridine benzoyl hydrazones: Antimicrobial activity. *J. Braz. Chem. Soc.* **2010**, *21*, 1247-1257.
 12. Despaigne, A.A.R.; Da Silva, J.G.; Do Carmo, A.C.M.; Piro, O.E.; Castellano, E.E.; Beraldo, H. Structural studies on zinc(II) complexes with 2-benzoylpyridine-derived hydrazones. *Inorg. Chim. Acta* **2009**, *362*, 2117-2122.
 13. Despaigne, A.A.R.; Da Silva, J.G.; Do Carmo, A.C.M.; Piro, O.E.; Castellano, E.E.; Beraldo, H. Copper(II) and zinc(II) complexes with 2-benzoylpyridine-methyl hydrazone. *J. Mol. Struct.* **2009**, *920*, 97-102.
 14. Coolier, H.O.J.; Dinneen, L.C.; Johnson, C.A.; Schneider, C. Abdominal constriction response and its suppression by analgesic drugs in the mouse. *Brit. J. Pharmacol.* **1968**, *32*, 295-310.
 15. Hunskar, S.; Hole, K. The formalin test in mice: Dissociation between inflammatory and noninflammatory pain. *Pain* **1987**, *30*, 103-114.
 16. Eddy, N.B.; Leimbach, D. Synthetic analgesics. II. Dithienylbutenylamines and dithienylbutylamines. *J. Pharmacol. Exp. Ther.* **1953**, *107*, 385-393.
 17. Doherty, N.S.; Poubelle, P.; Borgeat, P.; Beaver, T.H.; Westrich, G.L.; Schrader, N.L. Intraperitoneal injection of zymosan in mice induces pain, inflammation and the synthesis of peptidoleukotrienes and prostaglandin E₂. *Prostaglandins* **1985**, *30*, 769-789.
 18. Da Silva, Y.K.C.; Augusto, C.V.; Barbosa, M.L.C.; Melo, G.M.A.; De Queiroz, A.C.; Dias, T.L.M.F.; Bispo, W., Jr.; Barreiro, E.J.; Lima, L.M.; Alexandre-Moreira, M.S. Synthesis and pharmacological evaluation of pyrazine *N*-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. *Bioorg. Med. Chem.* **2010**, *18*, 5007-5015.
 19. Dutta, M.M.; Goswami, B.N.; Katak, J.C.S. Studies on biologically-active heterocycles. III. Synthesis and antibacterial activity of some 2-aryl/arakyl-3-substituted-4-thiazolidinones. *J. Indian Chem. Soc.* **1990**, *67*, 332-334.
 20. Ainscough, E.W.; Brodie, A.M.; Denny, W.A.; Finlay, G.J.; Gothe, S.A.; Ranford, J.D. Cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure-activity relationships. *J. Inorg. Biochem.* **1999**, *77*, 125-133.
 21. Enraf-Nonius. *COLLECT*; Nonius BV: Delft, The Netherlands, 1997-2000.
 22. Otwinowski, Z.; Minor, W. *Methods in Enzymology*; Carter, C.W., Jr., Sweet, R.M., Eds.; Academic Press: New York, NY, USA, 1997; pp. 307-326.
 23. Sheldrick, G.M. *SHELXS-97. Program for Crystal Structure Resolution*; University of Göttingen: Göttingen, Germany 1997.

24. Sheldrick, G.M. *SHELXL-97. Program for Crystal Structures Analysis*; University of Göttingen: Göttingen, Germany 1997.

Sample Availability: Samples of the compounds H₂LASSBio-466, H₂LASSBio-1064 and complexes [Zn(LASSBio-466)H₂O]₂ (**1**) and [Zn(HLASSBio-1064)Cl]₂ (**2**) are available from the authors.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).